CLVLY:OTC-Clinuvel Pharmaceuticals Limited (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 22.86

Change

+0.36 (+1.58)%

Market Cap

USD 1.12B

Volume

5.01K

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering drugs for the treatment of patients with severe genetic and skin disorders worldwide. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity; and PR√ČNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited for launching SCENESSE under a named patient program for the treatment of patients with EPP in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-09 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

+0.44 (+0.63%)

USD159.44B 24.54 2.63
CMXHF CSL Limited

-2.95 (-1.45%)

USD92.60B 34.75 20.19
CSLLY CSL Limited

-0.81 (-0.79%)

USD92.51B 34.77 20.19
GNMSF Genmab A/S

+1.92 (+0.56%)

USD22.62B 29.84 3.09
SBHMY Sino Biopharmaceutical Limited

N/A

USD19.28B 44.50 3.49
SBMFF Sino Biopharmaceutical Limited

N/A

USD19.19B 47.95 3.69
UCBJY UCB SA

-0.42 (-0.85%)

USD18.36B 21.88 15.06
UCBJF UCB SA

+1.77 (+1.84%)

USD18.17B 21.69 15.06
PPTDF PeptiDream Inc

N/A

USD5.72B 145.32 0.75
GENSF Genus plc

N/A

USD4.56B 68.44 44.38

ETFs Containing CLVLY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 35.32% 57% F 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 35.32% 57% F 65% D
Trailing 12 Months  
Capital Gain 78.14% 56% F 57% F
Dividend Return 0.14% 9% F N/A N/A
Total Return 78.29% 56% F 56% F
Trailing 5 Years  
Capital Gain 632.56% 88% B+ 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 632.56% 88% B+ 87% B+
Average Annual (5 Year Horizon)  
Capital Gain 50.52% 66% D 76% C
Dividend Return 0.08% 11% F 5% F
Total Return 50.61% 65% D 75% C
Risk Return Profile  
Volatility (Standard Deviation) 62.55% 60% D- 40% F
Risk Adjusted Return 80.90% 97% A+ 95% A
Market Capitalization 1.12B 88% B+ 68% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 66.18 17% F 12% F
Price/Book Ratio 17.67 27% F 10% F
Price / Cash Flow Ratio 79.01 4% F 3% F
EV/EBITDA 55.49 18% F 8% F
Management Effectiveness  
Return on Equity 33.10% 93% A 95% A
Return on Invested Capital 23.43% 67% D+ 85% B
Return on Assets 14.31% 97% A+ 97% A+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.51 62% D- 67% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.